Huawei preps AI chip to challenge Nvidia: report
Wall Street Breakfast
Seeking Alpha
3.8 • 950 Ratings
🗓️ 28 April 2025
⏱️ 5 minutes
🧾️ Download transcript
Summary
Episode transcripts seekingalpha.com/wsb.
Show links:
Biggest stock movers Monday: TM, AMPY, and more
Big Tech faces high-stakes earnings week amid tariff jitters
Trump ties tariffs to potential tax cuts for middle-income earners
Shein is said to raise U.S. prices up to 377% with new tariffs looming
Sign up for our daily newsletter here and for full access to analyst ratings, stock quant scores, dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning. |
| 0:08.0 | Good morning. Today is Monday, April 28. I'm Julie Morgan. Huawei takes aim at Nvidia. Merk KGAA locks in a billion-dollar biotech buy and CrowdStrike boosts AI security. |
| 0:23.6 | Huawei Technologies is preparing to test its newest and most powerful artificial intelligence |
| 0:29.2 | processor. According to the Wall Street Journal on Sunday, some Chinese tech companies have |
| 0:34.5 | been approached by Huawei about testing the new Ascend 910D chip. Some people |
| 0:40.1 | familiar with the matter were quoted as saying that Huawei is scheduled to receive the first |
| 0:44.9 | samples of the processor as soon as late next month. The people reportedly said that the processor's |
| 0:50.8 | development is at an early stage and tests will be needed to evaluate its performance |
| 0:56.0 | and prepare it for customers. According to the report, the company is hopeful that its latest |
| 1:01.1 | ascend AI processors will have more power than Nvidia's H-100, a popular chip that was released in 2022. |
| 1:10.2 | Huawei did not immediately respond to a request for comment by seeking Alpha, |
| 1:15.3 | while an NVIDIA spokesperson declined to comment. |
| 1:19.5 | German healthcare and materials group Merck KGAA will acquire U.S. biotech company SpringWorks |
| 1:26.3 | Therapeutics to boost its cancer business. |
| 1:29.3 | Merk KGAA said the purchase price of $47 per share in cash represents an equity value of about |
| 1:36.6 | $3.9 billion, equivalent to an enterprise value of $3.4 billion or $3 billion euros, |
| 1:43.5 | when SpringWork's cash holdings are deducted. |
| 1:46.5 | Merck said last week the two companies were in late-stage discussions |
| 1:50.2 | over a bit of around $47 per SpringWorks share. |
| 1:54.3 | The planned acquisition is expected to immediately add revenue |
| 1:57.8 | and accelerate mid-to-long-term growth for the healthcare business of Merk KGAA. |
| 2:04.4 | Crowdstrike unveiled Charlotte AI-Agentic response in Charlotte AI agentic workflows under its securities |
... |
Transcript will be available on the free plan in 12 days. Upgrade to see the full transcript now.
Disclaimer: The podcast and artwork embedded on this page are from Seeking Alpha, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Seeking Alpha and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.